• Development And Validation Of Human Chemokine Assays

    The chemokine system belongs to a large family of inflammatory cytokines and receptors. Approximately 50 chemokines and 20 receptors have been identified and shown to play a critical role in tumor growth, inflammatory response, infection, autoimmune disorders, neoplasm, vascular diseases, and transplant rejection (Locati et al. 2005, Slettenaar and Wilson 2006).

  • Inaccurate Forecasting Is Here To Stay: Focus On Managing Risk Instead

    The single most important factor influencing pharmaceutical and biopharmaceutical decisions is demand forecasting. Forecasts impact decisions regarding capital cost, outsourcing for product commercialization, and many other critical aspects of production. It’s no secret that drug forecasts are notoriously incorrect, and often by large margins. John LaMattina, former president of Pfizer Global R&D, foresees no improvement in forecasting accuracy. How then, do companies minimize risk?

  • The Right Biomanufacturing Partner Can Improve Flexibility And Mitigate Risks From Forecasting

    While forecasts can never be 100% accurate, the goal for biopharmaceutical forecasters should be to minimize the degree of inaccuracies as much as possible. To reduce the impact of inaccurate forecasting over the life cycle of a product, companies need to focus on those variables that they have the most control over.

  • Challenges, Risks And Strategies For Biologic Substance Manufacturing

    From discussions with pharmaceutical and biotechnology industry leaders, it is clear that demand forecasting is a significant challenge when planning biologic drug substance production.

  • Advancing Safety and Efficacy Studies with Novel Surgical Applications

    Novel therapeutics such as gene and cell therapies, nanoparticles, and combination products requiring targeted delivery,  novel treatments for wound healing, cardiovascular disease, and bone regeneration,  and new medical device technologies call for innovative surgical procedures in preclinical trials to determine safety and efficacy.

More From Featured Articles


  • FDA Approves Genentech’s Xolair (omalizumab) For Allergic Asthma In Children

    Genentech, a member of the Roche Group , recently announced that the U.S. Food and Drug Administration (FDA) approved Xolair (omalizumab) to treat moderate to severe persistent asthma in children six to 11 years of age, who have had a positive skin test or in vitro reactivity to an airborne allergen and have symptoms that are inadequately controlled with inhaled corticosteroids4



Fume Hoods Fume Hoods
The ChemGARD and ChemGARD-RI fume hoods use continuous a flow bypass design, which is
Inhibitor Cocktails
Sigma Inhibitor Cocktails are designed for protein isolation research and offer effective protease or phosphatase inhibition...
Mobilespin Mobilespin
Models 126, PS126 and 128
Catalog of Supplies and Services Catalog of Supplies and Services
The Production Supplies and Services Catalog offers over 9,000 products to protect people, products, and processes in cleanrooms, controlled environments, and production areas...
Lipid Library
The Screen-Well Bioactive Lipid Library enables researchers to rapidly screen and identify ligands for orphan receptors...
Drug Process Development Drug Process Development

Althea’s complete range of drug Process Development capabilities offers the tools to address your needs. We develop processes for producing small quantities of proteins for early testing or establish robust, reliable and scalable processes that enable a strong commercial advantage. Althea also provides access to a proprietary drug delivery platform, called Crystalomics® technology, for the development of alternative drug delivery formulations of second generation drug substances.

More Featured Products


Cleaning Validation – Lessons Learned in the Trenches August 23, 2016
1pm-2:30pm EDT, Online Training
Cloud Computing In A GxP Environment: Three Key Success Factors August 24, 2016
1pm-2:30pm EDT, Online Training
More Upcoming Courses